Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
100%(1 trials)

Phase Distribution

Ph early_phase_1
1
33%
Ph phase_2
2
67%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Other(1)

Detailed Status

unknown1
Completed1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (33.3%)
Phase 22 (66.7%)

Trials by Status

unknown133%
completed133%
not_yet_recruiting133%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingearly_phase_1

Pharmacokinetic (PK) Study of Tafenoquine in Healthy Adults

NCT07373743
completedphase_2

Tafenoquine in Patients With Mild to Moderate COVID-19

NCT04533347
unknownphase_2

A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With Mild to Moderate COVID 19 Disease and Low Risk of Disease Progression

NCT05947812

Clinical Trials (3)

Showing 3 of 3 trials
NCT07373743Early Phase 1

Pharmacokinetic (PK) Study of Tafenoquine in Healthy Adults

Not Yet Recruiting
NCT04533347Phase 2

Tafenoquine in Patients With Mild to Moderate COVID-19

Completed
NCT05947812Phase 2

A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With Mild to Moderate COVID 19 Disease and Low Risk of Disease Progression

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3